levodopa has been researched along with amantadine in 384 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 161 (41.93) | 18.7374 |
| 1990's | 57 (14.84) | 18.2507 |
| 2000's | 74 (19.27) | 29.6817 |
| 2010's | 65 (16.93) | 24.3611 |
| 2020's | 27 (7.03) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cox, B; Kastin, AJ; Schnieden, H | 1 |
| Greer, M | 2 |
| Agnoli, A; Carolei, A; Casacchia, M; Fazio, C; Zamponi, A | 1 |
| Morley, JB | 1 |
| Carroll, BJ; Curtis, GC; Kokmen, E | 1 |
| Winkelman, AC | 1 |
| Anand, M; Bhargava, KP; Gupta, GP | 1 |
| Wieck, HH | 1 |
| Kaumeier, S | 1 |
| Hungerbühler, JP; Regli, F | 1 |
| Jeste, DV; Wyatt, RJ | 1 |
| Przuntek, H | 1 |
| Postma, JU; Van Tilburg, W | 1 |
| Dinnendahl, V; Gumulka, SW; Peters, HD; Schönhöfer, PS | 1 |
| Lazarova, MB; Roussinov, KS | 2 |
| Hill, JW | 1 |
| Barbeau, A; Butterworth, RF; Campanella, G; Yamada, K | 1 |
| Cox, B; Tha, SJ | 1 |
| McFarland, HR | 1 |
| Gilbert, JC | 1 |
| Taylor, J | 1 |
| Beilin, B; Herishanu, Y; Rosenberg, P | 1 |
| Lazarova, M; Roussinov, K | 2 |
| Durand, JP; Gautier, JC | 1 |
| Agnoli, A; Squitieri, G | 1 |
| Savery, F | 2 |
| Calne, DB; Fahn, S | 1 |
| Agnoli, A; Casacchia, M; Ruggieri, S | 1 |
| Timberlake, WH; Vance, MA | 1 |
| Parkes, D | 2 |
| Fischer, PA; Jacobi, P; Schneider, E | 1 |
| Balík, J; Filip, V; Filipová, M; Krejcová, H; Rodný, J | 1 |
| Clemens, R | 1 |
| Selby, G | 1 |
| Marsden, CD; Mindham, RH; Parkes, JD | 1 |
| Marsden, CD | 1 |
| Barbeau, A; Gonce, M | 1 |
| Kunz, F; Lörincz, P; Ludin, HP; Ringwald, E | 1 |
| Couto, B; Freitas, MR; Mattos, JP; Oliveira, C | 1 |
| Fahn, S; Isgreen, WP | 1 |
| Bartholini, G; Haefely, W; Pletscher, A | 1 |
| McKinney, AS | 1 |
| Houeland, T; Sjaastad, O; Slettnes, O | 1 |
| Avila, C; Cabezas-Cerrato, J; Casanueva Freijo, F; Fernández-Cruz, A; Villanueva Aranguren, L | 1 |
| Fleming, AM; Lenman, JA; Reid, A; Turnbull, MJ | 1 |
| Fischer, GJ; Glass, J; Schubert, U | 1 |
| Mortimer, JA; Webster, DD | 1 |
| Aunis, D; Collard, M; Coquillat, G; Mandel, P; Miras Portugal, MT; Rohmer, F; Warter, JM | 1 |
| Feigenson, JS; McDowell, FH; Sweet, RD | 1 |
| Kadykov, AS | 2 |
| Baran, L; Maj, J; Sowińska, H | 1 |
| Iivanainen, M; Kaste, M | 1 |
| Bianchine, JR | 1 |
| Pakszys, W | 1 |
| Lapin, IP; Patkina, NA | 1 |
| Dolezalová, B; Vacek, J | 1 |
| Cotzias, GC; Ginos, JZ; Papavasiliou, PS | 1 |
| Kadykov, AS; Kistenev, BA; Pivovarova, VM | 1 |
| Evtushenko, SK | 1 |
| Bergen, D; Goetz, C; Klawans, HL | 1 |
| Völler, GW | 1 |
| Costall, B; Naylor, RJ | 2 |
| Baker, J; Iversen, LL; Iversen, SD; Pilling, JB; Robbins, T | 1 |
| Asselman, P; Bovill, KT; Marsden, CD; Parkes, JD; Phipps, JA; Rose, P; Tarsy, D | 1 |
| Callaghan, N; Fitzpatrick, E; O'Mahony, JB | 1 |
| Calne, DB | 3 |
| Ciunru, M; Gavril, A; Koropitzer, I; Merling, M; Nemteanu, E; Oprisan, C; Pendefunda, G; Pollingher, B; Stefanache, F | 1 |
| Boczán, G; Borus, F; Rózsa, L | 1 |
| Bermanzohn, PC; Lipper, S | 1 |
| Fernandez, FC; Lindsley, DF; Ranf, SK; Wyrwicka, W | 1 |
| Camanni, F; Isaia, GC; Massara, F; Molinatti, GM | 1 |
| Barnett, A; Goldstein, J | 1 |
| Barnett, A; Goldstein, JM; Malick, JB | 1 |
| Godwin-Austen, R | 1 |
| Camanni, F; Fassio, V; Massara, F; Molinatti, GM; Müller, EE | 1 |
| Galeone, F; Saba, GC; Saba, P; Salvadorini, F; Tognetti, G | 1 |
| Dandiya, PC; Kulkarni, SK | 1 |
| Parkenberg, H | 1 |
| Koller, WC | 2 |
| Siemers, E | 1 |
| Suitsu, N | 1 |
| Morgan, MY | 1 |
| Nakashima, K; Takahashi, K | 1 |
| Onodera, K; Shinoda, H | 1 |
| Jacobs, MB; Varon, J | 1 |
| Alistratov, AV; Balitskiĭ, KP; Syromiatnikov, AV | 1 |
| George, CF; Robertson, DR | 1 |
| Horiguchi, J; Inami, Y; Shoda, T | 1 |
| Bar, M; Graff, E; Isakov, M; Oberman, Z; Rabey, JM; Scharf, M | 1 |
| Goetz, CG; Klawans, HL; Rajput, AH; Tanner, CM; Thiessen, B; Uitti, RJ | 1 |
| Reynolds, CM; Riklan, M; Stellar, S | 1 |
| Slapal, R; Zouhar, A | 1 |
| Shannon, J; Tennant, F | 1 |
| Harvey, NS | 1 |
| Fujiwara, M; Kamiya, H; Ono, N; Saito, R | 1 |
| Huber, M | 1 |
| Bratton, M; Jost, MG; Lannon, MC; Lockhart-Pretti, P; Thomas, CA | 1 |
| Birkmayer, W | 1 |
| Aminoff, MJ | 1 |
| Bhalla, S; Mehta, VL; Wafai, ZA | 1 |
| Berman, ML; Tennant, F | 1 |
| Lieberman, AN | 1 |
| Fischer, R; Iizuka, J | 1 |
| Lakke, JP; Staal-Schreinemachers, AL | 1 |
| Iacono, RP; Sandyk, R; Snider, SR | 1 |
| Lazarus, A | 1 |
| Muenter, MD | 2 |
| Lakke, JP; Staal-Schreinemachers, AL; Wesseling, H | 1 |
| Flechter, S; Graff, E; Oberman, Z; Rabey, JM; Vardi, J | 1 |
| Fonda, D | 1 |
| Wirz, D | 1 |
| Grau-Veciana, JM; Peiró Grasa, A | 1 |
| Alfonsi, E; Horowski, R; Martignoni, E; Nappi, G; Sandrini, G | 1 |
| Grewaal, DS; McGeer, EG; McGeer, PL | 1 |
| Kadzielawa, K | 1 |
| Orland, HJ | 1 |
| Masi, G; Megna, GF; Puca, FM; Specchio, LM | 1 |
| Klawans, HL; Topel, JL | 1 |
| Bianchine, JR; Sunyapridakul, L | 1 |
| Hollmann, TD; Kravitz, EA | 1 |
| Callagham, N; Mcllroy, M; O'Connor, M | 1 |
| Calaghan, N; McIlroy, M; O'Connor, M | 1 |
| Klusha, VE; Kozlovskaia, MM; Svirskis, ShV; Val'dman, AV | 1 |
| Larsen, TA; Teräväinen, H | 1 |
| Weiner, M | 1 |
| West, AP | 1 |
| Colucci d'Amato, C; Cristillo, A; Puccini, A; Vizioli, R | 1 |
| Burton, K; Calne, DB | 1 |
| Busse, E; Riessbeck, KH; Rose, H | 1 |
| Jörg, J | 1 |
| Biesemeyer, H; Ludin, HP; Ringwald, E | 1 |
| Yaar, I | 1 |
| Lee, MC | 1 |
| Czuczwar, SJ; Kleinrok, Z; Kozicka, M | 1 |
| Busse, E; Helmholz, M; Krüger, B; Rose, H | 1 |
| van der Zee, HJ; van Nieuwenhuizen, O; Zweije-Hofman, IL | 1 |
| Alonso, RJ; Covington, TR; Mancall, EL | 1 |
| Quinn, NP | 1 |
| Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Morris, JG | 2 |
| Busse, E; Helmholz, M | 1 |
| Uono, M | 1 |
| Honda, Y; Kagono, Y; Kita, S; Saito, M; Suitsu, N | 1 |
| Colucci d'Amato, C; De Angelis, G; Giordano, L; Iaccarino, C; Marmo, E; Mastrosimone, F | 1 |
| Ando, K | 1 |
| Parkes, JD | 1 |
| Kase, M; Kuroiwa, Y; Narabayashi, H; Nishitani, Y; Ohmoto, T; Shiozawa, R; Toyokura, Y; Uono, K | 1 |
| Goetz, CG; Nausieda, PA; Tanner, CM | 1 |
| Schunk, W | 1 |
| Gerstenbrand, F; Gründig, E | 1 |
| Stewart, RM | 1 |
| Danielczyk, W | 2 |
| Hikiji, A; Ideshita, H; Morita, H; Sasaki, T; Yoshinaga, J | 1 |
| Pfaff, G | 1 |
| Bertha, G; Lechner, H; Ott, E | 1 |
| Ghika, J | 1 |
| Janjua, R; Roos, RA; van Kempen, GM | 1 |
| Sweeney, PJ | 1 |
| Danysz, W; Quack, G; Rogoz, Z; Skuza, G | 1 |
| Kawai, H; Mitsui, T; Miyata, M; Saito, S; Sakoda, S | 1 |
| Quinn, N | 1 |
| Hineno, T; Horiguchi, J; Kakimoto, Y; Mizobuchi, M; Nishimatsu, O | 1 |
| Lammers, GJ; Roos, RA | 1 |
| Kurisaki, H; Mizuno, T | 1 |
| Kornhuber, J; Weller, M | 1 |
| Durso, R; Folkerth, RD | 1 |
| Brownlee, HJ; Stacy, M | 1 |
| Kishore, A; Snow, BJ | 1 |
| Colosimo, C; Merello, M; Pontieri, FE | 1 |
| Pfeiffer, RF | 1 |
| Gordon, I; Rehavi, M; Weizman, R | 1 |
| Rundshagen, I | 1 |
| Lloyd, GK; Menzaghi, F; Rao, TS; Risbrough, VB; Whelan, KT | 1 |
| Ogawa, N | 1 |
| Kuno, S | 1 |
| Ajax, T; Dobson, J; Rodnitzky, R | 1 |
| Dike, GL | 1 |
| Camicioli, R; Ganzini, L; Young, BK | 1 |
| Kraus, MF; Maki, P | 1 |
| Scheidtmann, K; Schwarz, J; Trenkwalder, C | 1 |
| Kulisevsky, J; López-Villegas, D | 1 |
| Endo, S; Hikiji, A; Nakamura, Y; Yoshinaga, J | 1 |
| Oertel, WH; Quinn, NP | 1 |
| Hagell, P; Odin, P; Vinge, E | 1 |
| Gerritsen, JJ; Lammers, GJ; Meinders, AE; Roos, RA; van Laar, T | 1 |
| De Weerdt, W; Dom, R; Lesaffre, E; Nieuwboer, A | 1 |
| Chase, TN; Del Dotto, P; Fang, J; Mouradian, MM; van den Munckhof, P; Verhagen Metman, L | 1 |
| Ruggieri, S; Silver, DE | 1 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S | 1 |
| Galvez-Jimenez, N; Kumar, R; Lang, AE; Rajput, A; Rajput, AH; Uitti, RJ | 1 |
| Bhatia, K; Brooks, DJ; Burn, DJ; Clarke, CE; Playfer, J; Sawle, GV; Schapira, AH; Stewart, D; Williams, AC | 1 |
| Blanchet, PJ; Chase, TN; Del Dotto, P; van den Munckhof, P; Verhagen Metman, L | 1 |
| Danysz, W; Karcz-Kubicha, M; Quack, G | 1 |
| Roos, RA; van Hilten, JJ | 1 |
| Sunohara, N | 1 |
| Vale, S | 1 |
| Chase, TN; Del Dotto, P; Fang, J; Konitsiotis, S; LePoole, K; Metman, LV | 1 |
| Ahlskog, JE | 2 |
| Rascol, O | 1 |
| Bösch, S; Luginger, E; Poewe, W; Wenning, GK | 1 |
| Bhatia, KP; Münchau, A | 1 |
| Cersósimo, MG; Micheli, FE; Scorticati, MC | 1 |
| Bares, M; Hejduková, B; Hortová, H; Jech, R; Kanovský, P; Mecír, P; Rektor, I; Rektorová, I; Roth, J; Růzicka, E; Streitová, H | 1 |
| Arai, H; Ohrui, T; Sasaki, H; Yamaya, M; Yanai, M | 1 |
| Iwata, S; Kaseda, S; Nomoto, M | 1 |
| Giladi, N; Kandinov, B; Korczyn, AD; Orlov, Y; Paleacu, D; Shabtai, H; Simon, ES; Treves, TA | 1 |
| Eidelberg, D; Frucht, SJ; Scarmato, N; Scarmeas, N | 1 |
| Archer, T; Danysz, W; Fredriksson, A; Quack, G | 1 |
| Bernardini, S; Bonuccelli, U; Chase, TN; Del Dotto, P; Gambaccini, G; Metman, LV; Pavese, N | 1 |
| Carpinelli, A; Comi, G; Fazio, F; Gobbo, C; Messa, C; Moresco, RM; Rizzo, G; Volonté, MA | 1 |
| Onofrj, M; Paci, C; Thomas, A | 1 |
| Arai, H; Sasaki, H; Satou, T; Wada, H | 1 |
| Bandini, F; Bodis-Wollner, I; Pierantozzi, M | 1 |
| Clarke, CE | 1 |
| Finsterer, J | 1 |
| Suchowersky, O | 1 |
| Kapustina, MT; Karaban', IN; Karasevich, NV; Lukhanina, EP | 1 |
| Blanchet, PJ; Chase, TN; Metman, LV | 1 |
| Reingardiene, D | 1 |
| Clarke, CE; Crosby, N; Deane, KH | 1 |
| Bernardini, S; Bonuccelli, U; Dell'Agnello, G; Gambaccini, G; Lucetti, C; Petrozzi, L; Rossi, G | 1 |
| Arai, A; Kannari, K; Maeda, T; Matsunaga, M; Shen, H; Suda, T | 1 |
| Blackman, JA; Buck, ML; Conaway, MR; Patrick, PD | 1 |
| Okamoto, K; Tanaka, M | 1 |
| Shinohara, Y; Takahashi, H | 1 |
| Fernandez, HH; Okun, MS; Romrell, J | 1 |
| Ceballos-Baumann, A | 1 |
| Armellino, K; Di Iorio, A; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A | 1 |
| Bezard, E; Brotchie, JM; Crossman, AR; Grimée, R; Hill, MP; Klitgaard, H; Michel, A; Ravenscroft, P | 1 |
| Sobolewski, P | 1 |
| Takáts, A | 1 |
| Derejko, M; Friedman, A; Sławek, J; Zach, M | 1 |
| Filiano, JJ; Furukawa, Y; Kish, SJ | 1 |
| Jung, SK | 1 |
| Charles, PD; Covington, CD; Davis, TL; Fang, JY; Gill, CE; Konrad, PE; Newman, WJ; Padaliya, BB; So, SA; Tramontana, MG | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Lee, J | 1 |
| Kurlan, R | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Waters, C | 1 |
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Elovic, EP; Napolitano, E; Qureshi, AI | 1 |
| Lang, AE | 1 |
| Braga-Neto, P; da Silva-Júnior, FP; de Bruin, VM; Sueli Monte, F | 1 |
| Lees, A | 1 |
| Bibbiani, F; Chase, TN; Collins, MA; Kielaite, A; Oh, JD; Smith, C | 1 |
| Kitagawa, M; Tashiro, K | 1 |
| Artem'ev, DV | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Antico, J; Merello, M; Obeso, JA; Perez-Lloret, S | 1 |
| Brown, LA; Doan, J; Pellis, SM; Suchowersky, O; Whishaw, IQ | 1 |
| Brodsky, MA; Koudelka, C; Swarztrauber, K | 1 |
| Asmus, F; Bötzel, K; Deutschländer, A; Gasser, T; Klopstock, T; Marelli, E | 1 |
| Hattori, T; Sakakibara, R; Uchiyama, T | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Pires, D; Visanji, NP; Voon, V | 1 |
| Friedman, A; Koziorowski, D | 1 |
| Giroux, ML | 1 |
| Benecke, R; Wolters, A | 1 |
| Hattori, N | 1 |
| De Deyn, PP; Hauser, RA; Jon Stoessl, A; Korczyn, AD; Lang, AE; Poewe, W; Rascol, O; Watts, RL | 1 |
| Chen, JJ; Swope, DM | 1 |
| Klivényi, P; Vécsei, L | 1 |
| Dikshit, M; Husain, M; Khanna, VK; Maheshwari, PK; Nag, D; Seth, PK; Shukla, R; Srimal, RC | 1 |
| Bernardi, S; Edito, F; Meco, G; Purcaro, C; Stirpe, P; Valente, M; Vanacore, N | 1 |
| Stacy, M | 1 |
| Ikeda, K; Kurokawa, T; Mochizuki, H; Nakao, K; Yoshikawa, S; Yuzawa, N | 1 |
| Hayashi, R; Katsumata, Y; Mimura, M; Yamaguchi, S | 1 |
| Cao, HM; Guo, F; Qiao, J; Qu, QM; Wang, RL; Zhe, X | 1 |
| Auff, E; Haubenberger, D; Hochschorner, G; Katzenschlager, R; Kloiber, I; Ott, E; Poewe, W; Ransmayr, G; Schwingenschuh, P; Seppi, K; Wolf, E | 1 |
| Aubut, JA; Bayley, M; Foley, N; Marshall, S; Megyesi, J; Meyer, MJ; Meythaler, J; Murie-Fernandez, M; Salter, K; Teasell, R | 1 |
| Kapsoritakis, AN; Kardasi, M; Manolakis, AC; Potamianos, SP; Psychos, AK; Tsiopoulos, FD | 1 |
| Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N | 1 |
| Bentivoglio, AR; Fasano, A; Pettorruso, M; Ricciardi, L | 1 |
| Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B | 1 |
| Jeon, BS; Kim, HJ; Lee, JY | 1 |
| Fregni, F; Oliveira, L | 1 |
| Bido, S; Marti, M; Morari, M | 1 |
| Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 1 |
| Bezard, E; Fisone, G | 1 |
| Crossman, AR; Hill, MP; Kobylecki, C; Ravenscroft, P | 1 |
| Aguilar-Venegas, LC; Espinola-Nadurille, M; Fricchione, GL; Merida-Puga, J; Ramirez-Bermudez, J | 1 |
| Amato, L; Davoli, M; Minozzi, S; Pani, PP; Solimini, R; Vecchi, S; Zuccaro, P | 1 |
| Grice, T; Stagg, P | 1 |
| Fernandez, HH | 1 |
| Tarsy, D | 1 |
| Chen, R; Elahi, B; Phielipp, N | 1 |
| Ait Benhaddou, EH; Benjelloun, H; Benomar, A; Lachhab, L; Razine, R; Regragui, W; Yahyaoui, M | 1 |
| Joutsa, J; Kaasinen, V; Martikainen, K; Vahlberg, T | 1 |
| Berger, SP; Giuffrida, A; Johnson, SW; Macheda, T; Martinez, AA; Meshul, CK; Paquette, MA | 1 |
| Bagyeva, GKh; Dobrotvorskaia, IS; Fedorova, TN; Illarioshkin, SN; Ivanova-Smolenskaia, IA; Polevaia, EV; Stepanova, MS | 1 |
| Breger, LS; Dunnett, SB; Lane, EL | 1 |
| Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
| Nakagawasai, O; Nemoto, W; Sato, S; Tadano, T; Tan-no, K; Taniguchi, R; Yamadera, F; Yaoita, F | 1 |
| Sheehan, J; Thorpe, M; Wilson, L | 1 |
| Brotchie, JM; Fox, SH; Graef, JD; Hill, MP; Huot, P; James, JW; Johnston, TH; Jordan, KG; Koprich, JB; Letchworth, SR; Szeliga, KT | 1 |
| Hernández-Vara, J; Salvado, M | 1 |
| Gelfius, CD; Mortimer, D; Potts, MA | 1 |
| Kulisevsky, J; Pagonabarraga, J | 1 |
| Azulay, JP; Bonnet, AM; Brefel-Courbon, C; Corvol, JC; Damier, P; Dellapina, E; Destée, A; Durif, F; Galitzky, M; Lebouvier, T; Meissner, W; Ory-Magne, F; Rascol, O; Salis, A; Sommet, A; Thalamas, C; Tison, F; Viallet, F; Vidailhet, M | 1 |
| Narayanan, NS; Rodnitzky, RL | 1 |
| Capone, JG; Contini, E; Golfre-Andreasi, N; Gragnaniello, D; Preda, F; Quatrale, R; Sensi, M; Sette, E; Tola, MR; Trevisani, L; Tugnoli, V | 1 |
| Carta, M; Collu, M; Fidalgo, C; Gardoni, F; Morelli, M; Stancampiano, R; Tronci, E; Zianni, E | 1 |
| Hayashi, R; Kohsaka, M; Oeda, T; Sawada, H; Sudoh, S; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K | 1 |
| Bezard, E; Dufour, A; Facheris, MF; Ko, WK; Li, Q; McGuire, S; Pioli, E; Sherer, TB | 1 |
| Lewitt, PA; Mouradian, MM | 1 |
| Hauser, RA; Isaacson, S; McClure, NL; Pahwa, R; Ruby, AE; Sethi, K; Stempien, MJ; Struck, L; Tanner, CM; Truong, D; Went, GT | 1 |
| Amato, L; Davoli, M; De Crescenzo, F; Minozzi, S; Pani, PP; Solimini, R; Vecchi, S; Zuccaro, P | 1 |
| Bonuccelli, U; Ceravolo, R; Frosini, D; Mazzucchi, S | 1 |
| Jeon, BS; Park, H; Park, SH; Shin, JH | 1 |
| Canning, SD; Wang, XP; Zhang, LL | 1 |
| Bariotto-Dos-Santos, KD; Bortolanza, M; da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M | 1 |
| Jankovic, J; Vijayakumar, D | 1 |
| Herz, DM; Løkkegaard, A; Siebner, HR; Thomsen, BL | 1 |
| Hiller, A; Seier, M | 1 |
| Agarwal, P; Hauser, RA; Hull, KL; Isaacson, SH; Johnson, R; Lyons, KE; Nausieda, PA; Pahwa, R; Stempien, MJ; Tanner, CM; Truong, DD | 1 |
| Wagle Shukla, A | 2 |
| Felt, L; Hauser, RA; Isaacson, SH; Johnson, R; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM | 1 |
| Azulay, JP; Eggert, K; Ehret, R; Felt, L; Hauser, RA; Isaacson, S; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM; Trenkwalder, C | 1 |
| Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Lee, TG; Noh, JR; Park, HY; Ryu, YK | 1 |
| Hauser, RA; Pahwa, R | 1 |
| Perez-Lloret, S; Rascol, O | 1 |
| Bahroo, LB; Elkurd, MT; Pahwa, R | 1 |
| Keam, SJ; Paik, J | 1 |
| Dashtipour, K; Lyons, KE; Pahwa, R; Tafreshi, AR | 1 |
| Kuhn, W; Möhr, JD; Müller, T | 1 |
| Elmer, LW; Hauser, RA; Howard, R; Johnson, R; Kreitzman, DL; Kremens, DE; Nguyen, JT; Patni, R; Walsh, RR | 1 |
| Möhr, JD; Müller, T | 1 |
| Espiritu, AI; Jamora, RDG; Pajo, AT | 1 |
| Clark, I; Egan, T; Rentsch, P; Stayte, S; Vissel, B | 1 |
| Afonso, ND; Chapela, D; Correia, AD; Outeiro, TF; Sousa, S; van der Linde, HC; Vaz, RL; Willemsen, R | 1 |
| Arkadir, D; Bergman, H; Eitan, R; Hajyahya, A; Israel, Z; Linetsky, E; Snineh, MA | 1 |
| Chernick, D; Hauser, RA; Hubble, J; Isaacson, SH; Jankovic, J; Johnson, R; Oertel, WH; Pahwa, R; Tanner, CM | 1 |
| Cao, X; Chen, G; Cheng, C; Nie, S; Tan, Y; Wang, J; Xu, Y; Yang, X; Zeng, W; Zhang, Z; Zheng, C | 1 |
| Anheim, M; Grillon, A; Lipsker, D; Moegle, C; Velter, C | 1 |
| Arakawa, K; Maehara, S; Yuge, N | 1 |
| George, AL; Mitra, A; Ren, W; Shen, W; Surmeier, DJ; Vanoye, CG; Yang, B; Zhai, S | 1 |
| AlShimemeri, S; Fox, SH; Visanji, NP | 1 |
| Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A | 1 |
| Lee, AJ; Poon, LH; Vuong, M; Zuzuarregui, JR | 1 |
| Katunina, EA | 1 |
| Jost, WH; Koschel, J; Raeder, V; Ray Chaudhuri, K; Thiel, M; Tönges, L | 1 |
| Feldman, M; Margolesky, J; Marmol, S; Singer, C | 1 |
| Fabbri, M; Poewe, W; Rascol, O | 1 |
| Müller, T | 1 |
| Lin, CH; Lin, FJ; Tai, CH; Wang, CC; Wu, RM; Wu, TL | 1 |
| deVries, T; Jacobs, D; Jaros, M; Quartel, A; Rascol, O; Tönges, L | 1 |
| Arias-García, M; Bargas, J; Calderón, VM; Galarraga, E; Gómez-Paz, A; Lara-González, E; Luna-Leal, A; Ramírez-López, F | 1 |
| Bishop, C; Budrow, C; Centner, A; Cohen, SR; Coyle, M; Glinski, J; Lipari, N; Manfredsson, FP; Smith, S; Terry, ML; Wheelis, E | 1 |
| Takeda, A | 1 |
| Christensen, KV; Fryland, T; Hansen, JB; Mikkelsen, JD; Stoica, A; Thomsen, M | 1 |
| Bourque, M; Di Paolo, T; Dickens, D; Grégoire, L; Patel, W; Snodgrass, R | 1 |
| Ayala-Torres, JD; Calvo-Torres, F; Gaviria-Mendoza, A; Machado-Alba, JE; Valencia-Vásquez, A | 1 |
| Furukawa, T; Kinoshita, I; Kon, T; Murakami, Y; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M | 1 |
| Barbara, JM; Pace, A | 1 |
| Caron, MG; Jin, J; Martini, ML; Pogorelov, VM; Wetsel, WC | 1 |
94 review(s) available for levodopa and amantadine
| Article | Year |
|---|---|
[Considerations in the drug treatment of parkinsonism (author's transl)].
Topics: Amantadine; Apomorphine; Bromocriptine; Dopamine; Ergolines; Extrapyramidal Tracts; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Parkinson Disease; Phosphodiesterase Inhibitors; Piribedil; Tremor | 1978 |
In search of treatment for tardive dyskinesia: review of the literature.
Topics: Amantadine; Antipsychotic Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium; Methylphenidate; Parasympatholytics; Parasympathomimetics; Patient Dropouts; Research Design | 1979 |
[Therapy of tparkinson's disease. Clinical and pharmacological viewpoints].
Topics: Adrenergic beta-Antagonists; Amantadine; Bromocriptine; Histamine H1 Antagonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; MSH Release-Inhibiting Hormone; Muscle Rigidity; Parasympatholytics; Parkinson Disease; Posture; Psychoses, Substance-Induced; Tremor | 1979 |
[Memory, biochemical and pharmacological problems].
Topics: Amantadine; Amphetamine; Brain; Catecholamines; Humans; Levodopa; Memory, Short-Term; Paired-Associate Learning; Physostigmine; Reserpine | 1977 |
Considerations in the management of parkinsonism.
Topics: Amantadine; Carboxy-Lyases; Levodopa; Parasympatholytics; Parkinson Disease | 1978 |
Drug therapy: Bromocriptine.
Topics: Acromegaly; Adenoma; Amantadine; Bromocriptine; Female; Galactorrhea; Growth Hormone; Humans; Infertility; Lactation; Levodopa; Male; Parkinson Disease; Pituitary Neoplasms; Pregnancy; Prolactin | 1979 |
Treatment of parkinsonism.
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1976 |
Advances in the management of parkinson's disease.
Topics: Amantadine; Anesthesia; Humans; Levodopa; Orphenadrine; Parasympatholytics; Parkinson Disease; Social Adjustment; Trihexyphenidyl | 1976 |
[The current treatment of Parkinson's disease].
Topics: Amantadine; Antidepressive Agents, Tricyclic; Dihydroxyphenylalanine; Drug Combinations; Histamine Antagonists; Humans; Levodopa; Mental Disorders; Movement Disorders; Neurosecretory Systems; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Pyridoxine; Stereotaxic Techniques | 1976 |
Monoaminergic drugs: general pharmacology.
Topics: Absorption; Amantadine; Amphetamine; Animals; Apomorphine; Brain; Catecholamines; Cats; Cattle; Deamination; Decarboxylation; Dogs; Half-Life; Haplorhini; Humans; Hydroxylation; Kinetics; Levodopa; Methylation; Mice; Rats | 1976 |
[Progress in therapy of Parkinsonian syndrome].
Topics: Amantadine; Carboxy-Lyases; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease, Secondary; Postoperative Care; Stereotaxic Techniques; Sympathomimetics | 1975 |
Drug treatment of spasticity and rigidity.
Topics: Amantadine; Baclofen; Diazepam; Humans; Levodopa; Mephenesin; Muscle Rigidity; Parasympatholytics; Phenols; Phenothiazines; Spasm; Spinal Nerve Roots | 1975 |
Initiating treatment of Parkinson's disease.
Topics: Amantadine; Antioxidants; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide | 1992 |
Recent progress in the treatment of Parkinson's disease.
Topics: Amantadine; Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1992 |
The treatment of chronic hepatic encephalopathy.
Topics: Amantadine; Amino Acids, Branched-Chain; Anti-Bacterial Agents; Bromocriptine; Dietary Proteins; Hepatic Encephalopathy; Humans; Lactulose; Levodopa; Liver Cirrhosis; Receptors, GABA-A | 1991 |
Drug therapy for Parkinson's disease in the elderly.
Topics: Aged; Amantadine; Antiparkinson Agents; Carboxy-Lyases; Dopamine Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1990 |
Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions.
Topics: Amantadine; Antiparkinson Agents; Atrophy; Brain; Bromocriptine; Cognition; Dementia; Dreams; Drug Interactions; Ergolines; Humans; Levodopa; Libido; Memory; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Sexual Behavior; Substance-Related Disorders; Visual Perception | 1986 |
[Parkinson disease. The clinical picture and therapy].
Topics: Adrenergic beta-Antagonists; Amantadine; Bromocriptine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease | 1988 |
Parkinson's disease in the elderly: psychiatric manifestations.
Topics: Aged; Amantadine; Depression; Humans; Levodopa; Mood Disorders; Parasympatholytics; Parkinson Disease; Personality Disorders | 1985 |
Update on the treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Synergism; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline; Time Factors | 1985 |
Amantadine.
Topics: Acetylcholine; Amantadine; Animals; Antiviral Agents; Basal Ganglia Diseases; Behavior, Animal; Catecholamines; Chemical Phenomena; Chemistry; Dogs; Dopamine; Electroencephalography; Guinea Pigs; Haplorhini; Hemodynamics; Humans; Kinetics; Levodopa; Mice; Movement Disorders; Parasympatholytics; Parkinson Disease; Rabbits; Rats; Serotonin; Virus Diseases | 1974 |
Individualization of levodopa therapy.
Topics: Amantadine; Amphetamine; Anesthetics; Animals; Antihypertensive Agents; Apomorphine; Arrhythmias, Cardiac; Carbidopa; Depression, Chemical; Diet; Disulfiram; Drug Interactions; Drug Therapy, Combination; Endocrine Glands; Glaucoma; Humans; Hydrogen-Ion Concentration; Levodopa; Mice; Parasympatholytics; Parkinson Disease; Stomach | 1974 |
[Therapy of Parkinsonism. II].
Topics: Amantadine; Amitriptyline; Humans; Imipramine; Levodopa; Parkinson Disease; Physical Therapy Modalities | 1974 |
Update on antiparkinsonian agents.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Gastrointestinal Diseases; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Selegiline; Vascular Resistance | 1982 |
[Biochemical bases of Parkinson disease].
Topics: Acetylcholine; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Selegiline; Serotonin; Substantia Nigra; Tyrosine 3-Monooxygenase | 1984 |
Pharmacology of Parkinson's disease.
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Biopterins; Dopamine; Histamine H1 Antagonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Norepinephrine; Parasympatholytics; Parkinson Disease | 1984 |
Anti-parkinsonian drugs today.
Topics: Amantadine; Amphetamines; Antiparkinson Agents; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Dopamine beta-Hydroxylase; Droxidopa; Humans; Kinetics; Levodopa; Mental Disorders; Parasympatholytics; Parkinson Disease; Selegiline | 1984 |
[Antiparkinsonian drugs (author's transl)].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Receptors, Dopamine | 1980 |
Adverse effects of antiparkinsonian drugs.
Topics: Amantadine; Amphetamines; Antiparkinson Agents; Dyskinesia, Drug-Induced; Ergot Alkaloids; Humans; Hypotension; Levodopa; Mental Disorders; Parasympatholytics; Vomiting | 1981 |
The management of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Bromocriptine; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Hypotension, Orthostatic; Levodopa; Middle Aged; Nausea; Parasympatholytics; Parkinson Disease | 1982 |
Parkinson's disease: managing symptoms and preserving function.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Delayed-Action Preparations; Drug Combinations; Fetal Tissue Transplantation; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
Drug treatment of Parkinson's disease.
Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Cholinergic Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1995 |
Treatment options for early Parkinson's disease.
Topics: Algorithms; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline | 1996 |
Drug management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease; Selegiline; Trihexyphenidyl | 1996 |
Twenty-five years of amantadine therapy in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1995 |
[New therapeutic strategy for Parkinson's disease based on pharmacological profiles].
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1997 |
[Treatment of Parkinson's disease with multiple drugs].
Topics: Amantadine; Bromocriptine; Cholinergic Antagonists; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide | 1997 |
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.
Topics: Aging; Akathisia, Drug-Induced; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic Antagonists; Delirium; Dementia; Depression; Dopamine Agonists; Electroconvulsive Therapy; Humans; Levodopa; Memantine; Monoamine Oxidase Inhibitors; Psychoses, Substance-Induced; Risk Factors; Serotonin Antagonists | 1997 |
[Initial treatment of Parkinson's disease].
Topics: Amantadine; Antioxidants; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease | 1997 |
Early idiopathic parkinsonism: initiation and optimization of treatment.
Topics: Amantadine; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Selegiline | 1994 |
Parkinson's disease: drug therapy.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesia, Drug-Induced; Guidelines as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome | 1997 |
Pregnancy in Parkinson's disease: a review of the literature and a case report.
Topics: Abnormalities, Drug-Induced; Adjuvants, Pharmaceutic; Adult; Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Levodopa; Mice; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Rabbits; Rats; Selegiline | 1998 |
Initiating therapy for Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1998 |
[Drug therapy in Parkinson's disease].
Topics: Amantadine; Antiparkinson Agents; Clozapine; Dopamine Agonists; Dopamine Antagonists; Female; History, 19th Century; History, 20th Century; Humans; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Substantia Nigra | 1999 |
[Toxic and adverse neurological effects of anti-parkinsonian drugs].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Cholinergic Antagonists; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroleptic Malignant Syndrome; Psychoses, Substance-Induced; Substance-Related Disorders | 1999 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Medical treatment of levodopa-induced dyskinesias.
Topics: Amantadine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
Pharmacological treatment of Parkinson's disease.
Topics: Age Factors; Aged; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Diagnosis, Differential; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease | 2000 |
Interventions to prevent pneumonia among older adults.
Topics: Aged; Amantadine; Angiotensin-Converting Enzyme Inhibitors; Cerebrovascular Disorders; Gastroesophageal Reflux; Humans; Infection Control; Influenza Vaccines; Influenza, Human; Levodopa; Oral Hygiene; Pneumococcal Vaccines; Pneumonia; Pneumonia, Aspiration; Risk Factors; Substance P | 2001 |
[Pharmacological treatments of Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Genetic Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Tolcapone | 2001 |
[Parkinson disease: diagnostic and therapeutic criteria].
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Female; Globus Pallidus; Humans; Indoles; Levodopa; Lewy Body Disease; Lisuride; Male; Mental Status Schedule; Neurosurgery; Parkinson Disease; Parkinsonian Disorders; Piribedil; Psychiatric Status Rating Scales; Serotonin Receptor Agonists; Stereotaxic Techniques; Supranuclear Palsy, Progressive; Surveys and Questionnaires; Thalamus | 2001 |
Parkinson's disease: medical treatment of moderate to advanced disease.
Topics: Amantadine; Anti-Anxiety Agents; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Cognition Disorders; Disease Progression; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2002 |
Renaissance of amantadine in the treatment of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2003 |
[Neuroleptic malignant syndrome].
Topics: Acute Kidney Injury; Adult; Amantadine; Bromocriptine; Carbidopa; Contraindications; Dantrolene; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Female; Humans; Intensive Care Units; Levodopa; Male; Muscle Relaxants, Central; Neuroleptic Malignant Syndrome; Prognosis; Rhabdomyolysis | 2002 |
Amantadine in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2003 |
[Diagnosis and therapy for patients with vascular parkinsonism].
Topics: Akinetic Mutism; Amantadine; Antiparkinson Agents; Cerebral Infarction; Dementia, Vascular; Diagnosis, Differential; Gait Disorders, Neurologic; Humans; Levodopa; Muscle Rigidity; Parkinson Disease, Secondary; Platelet Aggregation Inhibitors; Posture; Secondary Prevention; Tremor | 2003 |
Rationale for current therapies in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Cholinergic Antagonists; Clinical Trials as Topic; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome | 2003 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
[Treatment of Parkinson disease in patients with surgical problems].
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Health Status; Humans; Levodopa; Parkinson Disease; Postoperative Period | 2003 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Other pharmacological treatments for motor complications and dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskinesia, Drug-Induced; Gait; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Periodicity; Purinergic P1 Receptor Antagonists; Purines; Selegiline | 2005 |
Pharmacological stimulant treatment of neurocognitive and functional deficits after traumatic and non-traumatic brain injury.
Topics: Amantadine; Animals; Brain Injuries; Bromocriptine; Cognition Disorders; Dextroamphetamine; Humans; Levodopa; Methylphenidate | 2005 |
Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Muscarinic Antagonists; Parkinson Disease; Quality of Life | 2005 |
[Drug treatment for geriatric urinary disorders; current concept].
Topics: Aged; Aged, 80 and over; Amantadine; Cerebral Infarction; Cholinergic Antagonists; Cognition Disorders; Deamino Arginine Vasopressin; Diagnosis, Differential; Donepezil; Humans; Indans; Levodopa; Piperidines; Quality of Life; Serotonin Agents; Urination Disorders | 2006 |
Parkinson disease: managing a complex, progressive disease at all stages.
Topics: Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Gait; Humans; Levodopa; Parkinson Disease | 2007 |
[Diagnosis and treatment of tremor in Parkinson's disease and essential tremor].
Topics: Adrenergic beta-Antagonists; Amantadine; Anticonvulsants; Antiparkinson Agents; Deep Brain Stimulation; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Electroencephalography; Humans; Levodopa; Middle Aged; Parkinson Disease; Practice Guidelines as Topic; Primidone; Tremor | 2007 |
[Neuromuscular disorders due to adverse effects of antiparkinson agents].
Topics: Amantadine; Antiparkinson Agents; Catechols; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuromuscular Diseases; Nitriles; Trihexyphenidyl | 2007 |
Pharmacotherapy for Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2007 |
Acute management of acquired brain injury Part III: an evidence-based review of interventions used to promote arousal from coma.
Topics: Amantadine; Arousal; Brain Injuries; Bromocriptine; Coma, Post-Head Injury; Dopamine Agonists; Evidence-Based Medicine; Humans; Levodopa; Music Therapy; Randomized Controlled Trials as Topic; Recovery of Function | 2010 |
Pharmacological and electrical stimulation in chronic disorders of consciousness: new insights and future directions.
Topics: Amantadine; Chronic Disease; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agents; Humans; Levodopa; Persistent Vegetative State | 2011 |
Molecular mechanisms of l-DOPA-induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Genes, Immediate-Early; Humans; Levodopa; Neurons; Parkinson Disease; Receptor, Cannabinoid, CB1; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Signal Transduction; Sirolimus | 2011 |
Dopamine agonists for the treatment of cocaine dependence.
Topics: Amantadine; Bromocriptine; Cocaine-Related Disorders; Depression; Dopamine Agonists; Humans; Levodopa; Randomized Controlled Trials as Topic | 2011 |
Updates in the medical management of Parkinson disease.
Topics: Age Factors; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Cholinergic Antagonists; Disease Progression; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease | 2012 |
N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis.
Topics: Amantadine; Databases, Factual; Disability Evaluation; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Severity of Illness Index | 2012 |
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indans; Indoles; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Parkinson Disease; Serotonin Syndrome; Treatment Outcome | 2014 |
Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Administration Schedule; Drug Combinations; Hospitalization; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Nursing Care; Parkinson Disease | 2014 |
Dopamine agonists for the treatment of cocaine dependence.
Topics: Amantadine; Antidepressive Agents; Bromocriptine; Cocaine-Related Disorders; Depression; Dopamine Agonists; Humans; Levodopa; Randomized Controlled Trials as Topic; Selection Bias | 2015 |
Current treatment and future prospects of dopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Treatment Outcome | 2015 |
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Methylphenidate; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Selegiline; Treatment Outcome | 2016 |
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
Topics: Amantadine; Anti-Dyskinesia Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic | 2016 |
[Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
Topics: Amantadine; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon | 2017 |
Parkinson's disease and pregnancy: An updated review.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Female; Humans; Levodopa; Parkinson Disease; Pregnancy; Treatment Outcome | 2017 |
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Receptors, N-Methyl-D-Aspartate | 2018 |
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Drug Delivery Systems; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
Amantadine Extended-Release (GOCOVRI
Topics: Amantadine; Animals; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2018 |
Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Patient Compliance | 2019 |
Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
Topics: Accidental Falls; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Bias; Constipation; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Xerostomia | 2019 |
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Development; Drug Repositioning; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2020 |
Amantadine Associated Myoclonus: Case Report and Review of the Literature.
Topics: Aged, 80 and over; Amantadine; Hallucinations; Humans; Levodopa; Male; Myoclonus; Parkinson Disease | 2021 |
Implications of dopaminergic medication withdrawal in Parkinson's disease.
Topics: Amantadine; Dopamine; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Substance Withdrawal Syndrome | 2022 |
Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?
Topics: Amantadine; Animals; Antiparkinson Agents; Confusion; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parkinson Disease | 2021 |
Amantadine in the treatment of Parkinson's disease and other movement disorders.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
GOCOVRI
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2022 |
46 trial(s) available for levodopa and amantadine
| Article | Year |
|---|---|
[Treatment of parkinsonian syndromes by bromocriptin].
Topics: Aged; Amantadine; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Humans; Hypotension; Levodopa; Male; Movement Disorders; Nausea; Parkinson Disease, Secondary | 1977 |
Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry.
Topics: Aged; Amantadine; Basal Ganglia Diseases; Bromocriptine; Chorea; Clinical Trials as Topic; Depression; Drug Evaluation; Humans; Levodopa; Parkinson Disease; Tranquilizing Agents | 1978 |
Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Substance Withdrawal Syndrome | 1978 |
Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interview, Psychological; Levodopa; Male; Mental Status Schedule; Methyldopa; Middle Aged; Parkinson Disease; Placebos; Recurrence; Trihexyphenidyl | 1976 |
[Clinical experience with bromocriptine, a central dopaminergic stimulator].
Topics: Aged; Amantadine; Bromocriptine; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Trihexyphenidyl | 1976 |
The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Depression; Dibenzazepines; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Placebos | 1976 |
Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses.
Topics: Aged; Amantadine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Skills; Parkinson Disease | 1975 |
Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.
Topics: Activities of Daily Living; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanine; Disability Evaluation; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Motor Skills; Parkinson Disease; Time Factors | 1975 |
Amphetamines in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Amphetamine; Clinical Trials as Topic; Female; Humans; Isomerism; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Parkinson Disease, Postencephalitic; Posture; Structure-Activity Relationship; Tremor | 1975 |
Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
Topics: Aged; Amantadine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil; Placebos | 1975 |
The treatment with L-dopa and amantadine in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
The effect of Dopaflex and Viregyt-K on gait and postural disturbances of operated and non-operated Parkinsonian patients.
Topics: Amantadine; Clinical Trials as Topic; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Posture | 1975 |
[A computer-assisted EEG study on psychotropic properties of antiparkinsonian drugs].
Topics: Amantadine; Antiparkinson Agents; Biperiden; Bromocriptine; Electroencephalography; Glycolates; Humans; Levodopa; Male; Psychotropic Drugs; Thiophenes; Trihexyphenidyl | 1992 |
[Modification of Parkinson tremor by budipine. A comparative study with amantadine].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines; Random Allocation | 1986 |
Refinement in the measurement of treatment response with combined L-dopa and amantadine in Parkinsonism.
Topics: Aged; Amantadine; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Female; Humans; Intelligence; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Personality Inventory; Placebos; Psychological Tests; Vocabulary; Wechsler Scales | 1974 |
Treatment of Parkinson's Disease with levodopa and amantadine used as single drugs and in combined therapy.
Topics: Adult; Aged; Amantadine; Clinical Trials as Topic; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1974 |
An extended clinical trial to compare levodopa and amantadine used as single drugs with both drugs used incombination in Parkinson's Disease.
Topics: Amantadine; Clinical Trials as Topic; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1974 |
Anti-parkinson drugs in the Batten-Spielmeyer-Vogt syndrome; a pilot trial.
Topics: Adolescent; Adult; Amantadine; Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Lipidoses; Psychoses, Substance-Induced; Syndrome | 1982 |
[The additive effect of amantadine hydrochloride (Symmetrel) on parkinsonian patients receiving levodopa treatment (author's transl)].
Topics: Adult; Amantadine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Weekly drug holiday in Parkinson disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
[Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)].
Topics: Amantadine; Amino Acids; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Piperidines | 1980 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 1998 |
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
Topics: Amantadine; Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Severity of Illness Index | 1999 |
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2000 |
Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Levodopa; Male; Medical Records; Middle Aged; Movement Disorders; Parkinson Disease; Safety; Severity of Illness Index; Treatment Outcome | 2000 |
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Remission Induction | 2001 |
Amantadine for dyskinesia in patients affected by severe Parkinson's disease.
Topics: Aged; Amantadine; Antiviral Agents; Disease Progression; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Substance Withdrawal Syndrome; Treatment Outcome | 2001 |
The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Asian People; Black or African American; Cognition; Drug Therapy, Combination; Electrophysiology; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Treatment Outcome; Visual Perception | 2002 |
Amantadine in Huntington's disease: open-label video-blinded study.
Topics: Aged; Amantadine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Huntington Disease; Hyperkinesis; Levodopa; Male; Receptors, N-Methyl-D-Aspartate; Time Factors | 2002 |
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
Topics: Aged; Amantadine; Dopamine Agents; Double-Blind Method; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2004 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Placebos; Treatment Outcome | 2005 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Arm; Benzothiazoles; Biomechanical Phenomena; Carbidopa; Catechols; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 2006 |
Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Drug Administration Routes; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2007 |
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Topics: Aged; Amantadine; Antiparkinson Agents; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2007 |
Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mianserin; Middle Aged; Mirtazapine; Pilot Projects; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Serotonin; Treatment Outcome | 2009 |
Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2010 |
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2014 |
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2015 |
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; North America; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Prevalence | 2019 |
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
Topics: Aged; Amantadine; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease | 2020 |
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Topics: Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2022 |
244 other study(ies) available for levodopa and amantadine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Body Temperature; Brain; Dopamine; Female; Humans; Levodopa; Mice; Motor Activity; MSH Release-Inhibiting Hormone; Rats; Receptors, Drug; Stereotyped Behavior; Time Factors | 1976 |
How to achieve maximum benefit for the patient with Parkinson's disease.
Topics: Aged; Amantadine; Carbidopa; Diagnosis, Differential; Histamine H1 Antagonists; Humans; Levodopa; Nervous System Diseases; Occupational Therapy; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Psychotherapy; Trihexyphenidyl | 1976 |
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Piribedil; Pizotyline; Propranolol | 1976 |
Parkinson's disease.
Topics: Amantadine; Antidepressive Agents; Carbidopa; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities | 1977 |
Paradoxical response to dopamine agonists in tardive dyskinesia.
Topics: Adrenergic alpha-Agonists; Adult; Amantadine; Apomorphine; Benztropine; Clozapine; Deanol; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Antagonism; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Levodopa; Physostigmine; Receptors, Dopamine; Reserpine; Stimulation, Chemical; Thioridazine | 1977 |
Update on drug treatment of Parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1977 |
Modification of electroshock fighting by drugs known to interact with dopaminergic and noradrenergic neurons in normal and brain lesioned rats.
Topics: Aggression; Amantadine; Animals; Apomorphine; Brain; Ditiocarb; Dopamine; Electroshock; Humans; Imipramine; Levodopa; Male; Neurons; Norepinephrine; Rats; Reserpine | 1977 |
[Treatment of parkinson's syndrome. New developments].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents; Benzodiazepines; Carboxy-Lyases; Humans; Hyperkinesis; Levodopa; Parasympatholytics; Parkinson Disease; Tranquilizing Agents | 1978 |
[Parkinsonism].
Topics: Amantadine; Arteriosclerosis; Genes, Dominant; Guam; Histamine H1 Antagonists; Humans; Levodopa; Middle Aged; Parasympatholytics; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Physical Therapy Modalities; Speech Disorders | 1978 |
Drugs for Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Drug Evaluation; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Phenethylamines | 1978 |
Visual hallucinations and delirium during treatment with amantadine (Symmetrel).
Topics: Aged; Amantadine; Benztropine; Biperiden; Delirium; Drug Eruptions; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Orphenadrine; Parkinson Disease | 1975 |
Effects of dopaminergic stimulants on cyclic nucleotide levels in mouse brain in vivo.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Benserazide; Brain; Cerebellum; Cyclic AMP; Cyclic GMP; Dopamine; Dose-Response Relationship, Drug; Humans; Isoquinolines; Levodopa; Male; Mice; Nucleotides, Cyclic; Stereotyped Behavior | 1976 |
On certain relationships between gamma-aminobutyric acid (GABA) and dopaminergic agents in pentylenetetrazol convulsions.
Topics: Amantadine; Animals; Apomorphine; Dextroamphetamine; Ditiocarb; Dopamine; Drug Interactions; gamma-Aminobutyric Acid; Haloperidol; Levodopa; Male; Mice; Pentylenetetrazole; Seizures | 1978 |
In practice. Parkinson's disease.
Topics: Amantadine; Basal Ganglia; Bromocriptine; Humans; Levodopa; Middle Aged; Movement; Parasympatholytics; Parkinson Disease; Prognosis; Synaptic Transmission | 1979 |
Uptake and efflux of 14-C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Platelets; Carbon Radioisotopes; Depression, Chemical; Dopamine; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histamine H1 Antagonists; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Time Factors; Trihexyphenidyl | 1975 |
The role of dopamine and noradrenaline in temperature control of normal and reserpine-pretreated mice.
Topics: Amantadine; Animals; Apomorphine; Body Temperature; Body Temperature Regulation; Dextroamphetamine; Dopamine; Droxidopa; Esophagus; Female; Levodopa; Male; Mice; Mice, Inbred Strains; Norepinephrine; Reserpine; Time Factors | 1975 |
Treating parkinsonism in the era of levodopa.
Topics: Amantadine; Antidepressive Agents; Anxiety; Depression; Histamine H1 Antagonists; Humans; Levodopa; Occupational Therapy; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Psychotherapy; Tranquilizing Agents | 1975 |
Diseases of the central nervous system. Pharmacological basis of treatment.
Topics: Amantadine; Analgesics, Opioid; Anticonvulsants; Blood-Brain Barrier; Central Nervous System Diseases; Cholinesterase Inhibitors; Edrophonium; Epilepsy; Headache; Humans; Levodopa; Methysergide; Migraine Disorders; Myasthenia Gravis; Parkinson Disease; Pyridostigmine Bromide; Serotonin Antagonists | 1975 |
Parkinson's disease.
Topics: Amantadine; Benztropine; Humans; Levodopa; Parkinson Disease; Procyclidine; Trihexyphenidyl | 1977 |
Increased appetite (bulimia) in Parkinson's disease.
Topics: Aged; Amantadine; Feeding and Eating Disorders; Female; Humans; Hunger; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
On some relationships between dopaminergic and serotoninergic mechanisms in pentylenetetrazol convulsions in albino mice.
Topics: 5-Hydroxytryptophan; Amantadine; Amphetamine; Animals; Apomorphine; Dopamine; Levodopa; Male; Mice; Pentylenetetrazole; Seizures; Serotonin | 1979 |
[Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
Topics: Activities of Daily Living; Aged; Amantadine; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hyperkinesis; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Parasympatholytics; Parkinson Disease, Secondary; Therapeutic Equivalency; Time Factors | 1977 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1979 |
Electroretinographic changes in patients with parkinsonism treated with various classes of antiparkinsonian drugs.
Topics: Amantadine; Antiparkinson Agents; Electroretinography; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Retina | 1979 |
On certain effects of dopaminergic agents in pentylenetetrazol convulsions.
Topics: Amantadine; Animals; Benserazide; Dextroamphetamine; Dopamine; Drug Interactions; Haloperidol; Levodopa; Male; Mice; Pentylenetetrazole; Rats; Seizures | 1978 |
[Therapy of Parkinson's syndrome].
Topics: Amantadine; Benserazide; Carbidopa; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Reserpine; Stereotaxic Techniques | 1976 |
The shaking patient. Diagnosis and management of tremor.
Topics: Amantadine; Carbidopa; Cerebellar Diseases; Humans; Levodopa; Parkinson Disease; Propranolol; Tremor | 1977 |
[Treatment of parkinsonism].
Topics: Amantadine; Antiparkinson Agents; Carboxy-Lyases; Drug Combinations; Evaluation Studies as Topic; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Thalamus | 1977 |
[Amantadine potentiation of G.H. relase evoked by L-dopa and its inhibition by nonesterified fatty acids].
Topics: Adult; Amantadine; Drug Synergism; Fatty Acids, Nonesterified; Female; Growth Hormone; Humans; Levodopa; Male; Pituitary Gland; Stimulation, Chemical | 1977 |
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
Topics: Amantadine; Chorea; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methylhistamines; Middle Aged; Movement Disorders; Parkinson Disease; Phenylacetates; Tremor | 1977 |
Clinical and electromyographic examinations on the effect of hydrochloride (Viregyt-K) in the treatment of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Drug Therapy, Combination; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1977 |
Failure of L-dopa to relieve activated rigidity in Parkinson's disease.
Topics: Adult; Amantadine; Extrapyramidal Tracts; Hepatolenticular Degeneration; Humans; Levodopa; Male; Middle Aged; Muscle Contraction; Parkinson Disease; Penicillamine; Thalamus | 1977 |
[Dopamine beta hydroxylase. Value and limits of its study in neurology].
Topics: Amantadine; Cold Temperature; Dopamine beta-Hydroxylase; Epilepsy; Humans; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Quadriplegia | 1976 |
Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Topics: Aged; Amantadine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Movement Disorders; Parasympatholytics; Parkinson Disease; Piperazines; Piribedil | 1976 |
[The effectiveness of amantadine (midantan) in the treatment of the parkinsonian syndrome].
Topics: Amantadine; Arteriosclerosis; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary | 1976 |
Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy.
Topics: Amantadine; Animals; Anthracenes; Catalepsy; Drug Synergism; Female; Humans; Levodopa; Male; Physostigmine; Piperidines; Rats; Receptors, Drug; Reserpine; Serotonin; Tranquilizing Agents | 1976 |
[Treatment of parkinsonism].
Topics: Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1976 |
Drug therapy of parkinsonism.
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior; Dopa Decarboxylase; Drug Interactions; Humans; Levodopa; Parkinson Disease; Trihexyphenidyl | 1976 |
[Interaction between L-dopa and other drugs].
Topics: Amantadine; Anti-Arrhythmia Agents; Apomorphine; Chlorpromazine; Drug Antagonism; Drug Interactions; Drug Synergism; Humans; Levodopa; Parkinson Disease; Tranquilizing Agents | 1976 |
Effects of catecholaminergic drugs on systems of reward and punishment in experiments on cats.
Topics: Amantadine; Amphetamine; Animals; Behavior, Animal; Benserazide; Catecholamines; Cats; Disulfiram; Electric Stimulation; Electrodes, Implanted; Levodopa; Male; Punishment; Reward | 1976 |
[Modern antiparkinsonics (L-dopa and amantadine) and presentday psychiatry (author's transl)].
Topics: Amantadine; Humans; Levodopa; Mental Disorders; Parkinson Disease, Secondary; Psychotic Disorders | 1976 |
Therapeutic approaches in Parkinson's disease: possible roles of growth hormone and somatostatin.
Topics: Amantadine; Apomorphine; Growth Hormone; Humans; Levodopa; Parkinson Disease; Somatostatin | 1976 |
[Current drug treatment of parkinsonism].
Topics: Adult; Aged; Amantadine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1976 |
[Combined treatment of Parkinsonism with levopa, midantan and anticholinergic drugs].
Topics: Acetylcholine; Adult; Aged; Amantadine; Antiparkinson Agents; Cholinesterases; Drug Therapy, Combination; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Male; Middle Aged; Muscle Tonus; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Trihexyphenidyl | 1976 |
Levodopa-induced myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Amantadine; Amphetamine; Animals; Benztropine; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; Levodopa; Male; Methysergide; Middle Aged; Movement Disorders; Myoclonus; Parkinson Disease; Propranolol; Serotonin; Serotonin Antagonists; Sleep; Trihexyphenidyl | 1975 |
A comparison of circling models for the detection of antiparkinson activity.
Topics: Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior; Brain; Dextroamphetamine; Dopamine; Haloperidol; Humans; Isoquinolines; Levodopa; Male; Methylphenidate; Methyltyrosines; Piperazines; Rats; Reserpine; Rotation; Stereotaxic Techniques; Stereotyped Behavior; Substantia Nigra; Thalamic Nuclei | 1975 |
Letter: Electroconvulsive therapy in patients with parkinsonism.
Topics: Amantadine; Atropine; Depression; Diphenhydramine; Electroconvulsive Therapy; Female; Humans; Levodopa; Methohexital; Middle Aged; Parkinson Disease; Succinylcholine; Suicide | 1975 |
Effects of anti-parkinsonian drugs on the motor activity and EEG of cats with subthalamic lesions.
Topics: Amantadine; Animals; Antiparkinson Agents; Attention; Behavior, Animal; Benserazide; Cats; Cerebral Cortex; Cortical Synchronization; Dextroamphetamine; Diencephalon; Electroencephalography; Functional Laterality; Levodopa; Motor Activity; Neural Pathways; Reticular Formation | 1975 |
Dopaminergic control of growth hormone secretion in normal and acromegalic subjects.
Topics: Acromegaly; Amantadine; Bromocriptine; Ergolines; Growth Hormone; Humans; Hypothalamo-Hypophyseal System; Levodopa; Phentolamine; Pituitary Gland; Propranolol | 1975 |
Actions of dopaminergic agonists on motor function.
Topics: Amantadine; Animals; Apomorphine; Behavior; Dextroamphetamine; Disease Models, Animal; Dopamine Antagonists; Humans; Hyperkinesis; Levodopa; Methylphenidate; Motor Activity; Movement Disorders; Phenethylamines; Piribedil; Rats; Stereotyped Behavior; Tyrosine | 1975 |
Head-turning induced by electrical stimulation of the caudate nucleus and its antagonism by anti-parkinson drugs.
Topics: Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benztropine; Caudate Nucleus; Depression, Chemical; Electric Stimulation; Humans; Levodopa; Male; Rats; Stereotyped Behavior; Trihexyphenidyl | 1975 |
The evaluation of anti-parkinson drugs on reserpine-induced rigidity in rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Apomorphine; Benztropine; Carbidopa; Hindlimb; Levodopa; Male; Methamphetamine; Muscle Rigidity; Rats; Reserpine; Scopolamine; Time Factors; Trihexyphenidyl | 1975 |
The treatment of parkinsonism.
Topics: Amantadine; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary | 1975 |
Effect of five dopaminergic drugs on plasma growth hormone levels in acromegalic subjects.
Topics: Acromegaly; Adult; Aged; Amantadine; Bromocriptine; Ergolines; Female; Growth Hormone; Humans; Levodopa; Male; Memantine; Middle Aged; Piperazines; Piribedil | 1975 |
[Clinical studies on the activation of the GH-secreting system in man].
Topics: Adult; Amantadine; Growth Hormone; Humans; Hypothalamus; Levodopa; Male; Middle Aged | 1975 |
Influence of chemical stimulation of central dopaminergic system on the open field behaviour of rats.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benztropine; Brain; Dopamine; Levodopa; Male; Rats; Stimulation, Chemical | 1975 |
[Treatment of parkinsonism].
Topics: Amantadine; Benztropine; Biperiden; Humans; Levodopa; Orphenadrine; Parkinson Disease; Procyclidine; Trihexyphenidyl | 1976 |
Exteroceptive suppression of the masseter and temporalis muscles and parkinsonian rigidity.
Topics: Adult; Aged; Amantadine; Basal Ganglia; Bromocriptine; Electric Stimulation; Electromyography; Female; Humans; Levodopa; Male; Masseter Muscle; Middle Aged; Muscle Rigidity; Muscle Spindles; Parkinson Disease; Temporal Muscle; Trigeminal Nerve; Trihexyphenidyl | 1991 |
Pharmacological characteristics of catalepsy induced by intracerebroventricular administration of histamine in mice: the importance of muscarinic step in central cholinergic neurons.
Topics: Amantadine; Animals; Atropine; Biperiden; Bromocriptine; Catalepsy; Histamine; Injections, Intraventricular; Levodopa; Male; Mice; Neurons; Promethazine; Receptors, Muscarinic; Scopolamine; Trihexyphenidyl | 1991 |
Treating the progressive stages of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline | 1991 |
[Inhibition of the metastasis of Lewis lung carcinoma in mice by the administration of spasmolytin, midantan and L-DOPA].
Topics: Amantadine; Animals; Combined Modality Therapy; Diphenylacetic Acids; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Levodopa; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Postoperative Care; Preoperative Care | 1990 |
Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state.
Topics: Amantadine; Brain; Coma; Electroencephalography; Female; Humans; Levodopa; Middle Aged; Tomography, X-Ray Computed | 1990 |
Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson's disease.
Topics: Administration, Oral; Aged; Amantadine; Biperiden; Bromocriptine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Piperidines | 1990 |
Hypersexuality with antiparkinsonian therapy.
Topics: Adult; Age Factors; Aged; Amantadine; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Sex Factors; Sexual Behavior | 1989 |
Correlates of memory in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Memory; Memory Disorders; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease | 1989 |
[Therapeutic effect of dopaminergic substances in drug-resistant Lennox-Gastaut syndrome].
Topics: Amantadine; Child, Preschool; Epilepsy; Humans; Infant; Levodopa; Syndrome | 1989 |
Quantitative urine testing. A new tool for diagnosing and treating cocaine use.
Topics: Adolescent; Adult; Amantadine; Amino Acids; Cocaine; Female; Humans; Levodopa; Male; Radioimmunoassay; Substance-Related Disorders | 1989 |
Recent developments in the treatment of Parkinson's disease.
Topics: Aged; Aging; Amantadine; Diagnosis, Differential; Drug Administration Schedule; Dyskinesia, Drug-Induced; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Exertion | 1985 |
The effect of neurotransmitters on cataleptic behavior induced by PG D2 in rats.
Topics: Acetylcholine; Amantadine; Animals; Apomorphine; Catalepsy; Dopamine; Fenclonine; Injections, Intraventricular; Levodopa; Male; Motor Activity; Neurotransmitter Agents; Norepinephrine; Prostaglandin D2; Prostaglandins D; Rats; Rats, Inbred Strains; Serotonin; Time Factors | 1987 |
Comprehensive care of the patient with Parkinson's disease.
Topics: Aged; Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Muscle Rigidity; Parasympatholytics; Parkinson Disease; Patient Care Planning; Patient Care Team; Tremor | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
Parkinson's disease in the elderly: current management strategies.
Topics: Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1987 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1988 |
Attenuation of pentylenetetrazol kindling of epileptogenesis in rats by dopaminergic agents.
Topics: Amantadine; Amphetamine; Animals; Epilepsy; Haloperidol; Kindling, Neurologic; Levodopa; Male; Metoclopramide; Pentylenetetrazole; Rats | 1988 |
Stepwise detoxification from cocaine. A promising regimen.
Topics: Adolescent; Adult; Amantadine; Bromocriptine; Cocaine; Desipramine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Substance Withdrawal Syndrome; Substance-Related Disorders; Tryptophan; Tyrosine | 1988 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats | 1986 |
[Antiparkinson agents].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Lisuride; Parasympatholytics | 1987 |
Amantadine for levodopa resistant parkinsonism.
Topics: Aged; Amantadine; Drug Resistance; Female; Humans; Levodopa; Parkinson Disease | 1987 |
Therapy of neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Carbidopa; Combined Modality Therapy; Dantrolene; Diazepam; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroconvulsive Therapy; Humans; Levodopa; Neuroleptic Malignant Syndrome; Receptors, Dopamine | 1986 |
Pharmacotherapy: problems and practices.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1986 |
Drugs for parkinsonism.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1986 |
[Revision of the treatment strategy in Parkinson disease].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Care Planning | 1986 |
Selective regional effect of various neuroactive drugs on bromocriptine concentration in the brain of rats.
Topics: Amantadine; Animals; Biperiden; Brain Chemistry; Bromocriptine; Carbidopa; Diazepam; Haloperidol; Levodopa; Methysergide; Naloxone; Rats | 1986 |
Pharmacologic treatment of parkinsonian tremor.
Topics: Amantadine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor; Trihexyphenidyl | 1986 |
[Secondary effects of prolonged levodopa therapy in Parkinson's disease].
Topics: Age Factors; Aged; Amantadine; Antidepressive Agents, Tricyclic; Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Drug Therapy, Combination; Dystonia; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Parkinson Disease | 1985 |
Effects of lisuride on blink reflex habituation in Parkinson disease.
Topics: Adult; Aged; Amantadine; Blinking; Electrophysiology; Ergolines; Habituation, Psychophysiologic; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1985 |
Influence of noncholinergic drugs on rat striatal acetylcholine levels.
Topics: Acetylcholine; Acetylcholinesterase; Acetyltransferases; Amantadine; Animals; Anti-Anxiety Agents; Apomorphine; Benzodiazepines; Biological Assay; Brain Chemistry; Choline; Corpus Striatum; Depression, Chemical; Haloperidol; Levodopa; Male; Methamphetamine; Rats; Rats, Inbred Strains; Reserpine; Stimulation, Chemical; Tyrosine 3-Monooxygenase | 1974 |
Dopamine receptor in the reward system of the rat.
Topics: Amantadine; Animals; Apomorphine; Benzyl Compounds; Cortical Synchronization; Desipramine; Dihydroxyphenylalanine; Dopamine; Electrodes, Implanted; Electroencephalography; Haloperidol; Hydrazines; Hypothalamus; Levodopa; Male; Rats; Receptors, Drug; Reward; Self Stimulation; Time Factors | 1974 |
Case report: ventricular arrhythmias with L-dopa and amantadine hydrochloride therapy during halothane anaesthesia.
Topics: Aged; Amantadine; Anesthesia, Inhalation; Arrhythmias, Cardiac; Catecholamines; Epinephrine; Female; Halothane; Heart Ventricles; Humans; Levodopa | 1974 |
[Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Mental Processes; Parkinson Disease; Psychological Tests | 1974 |
Parkinsonism as a falling sickness.
Topics: Age Factors; Aged; Amantadine; Female; Gait; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parasympatholytics; Parkinson Disease; Posture; Reflex; Remission, Spontaneous; Tremor | 1974 |
[Psychopharmacologic spectrum of melanostatin].
Topics: Aggression; Amantadine; Animals; Behavior, Animal; Biogenic Amines; Brain Chemistry; Catalepsy; Cats; Depression; Emotions; Fever; Haloperidol; Humans; Levodopa; Motor Activity; MSH Release-Inhibiting Hormone; Reserpine | 1980 |
[Drug therapy of parkinsonism].
Topics: Amantadine; Bromocriptine; Dopamine Antagonists; Humans; Levodopa; Neurotransmitter Agents; Parasympatholytics; Parkinson Disease | 1982 |
Role of the relationships between the neurotransmitter systems in the convulsive-seizure reactions.
Topics: 5-Hydroxytryptophan; Amantadine; Amphetamine; Animals; Dopamine; Electroshock; gamma-Aminobutyric Acid; Kindling, Neurologic; Levodopa; Mice; Neurotransmitter Agents; Rats; Seizures; Serotonin | 1982 |
Treatments for neuroleptic malignant syndrome.
Topics: Adult; Amantadine; Antipsychotic Agents; Bromocriptine; Catatonia; Electroconvulsive Therapy; Fever; Humans; Levodopa; Male | 1984 |
[Effect of the cAMP and interferon levels in the lymphocytes and on a change in the tumor growth rate of a transplantable golden hamster melanoma after BCG, measles vaccine, L-DOPA and amantadine treatment].
Topics: Amantadine; Animals; BCG Vaccine; Cricetinae; Cyclic AMP; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Interferons; Levodopa; Lymph Nodes; Lymphocytes; Measles Vaccine; Melanoma; Mesocricetus; Neoplasm Transplantation; Neoplasms, Experimental | 1980 |
[Therapeutic concept in Parkinson disease].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents, Tricyclic; Benzodiazepines; Bromocriptine; Depression; Fludrocortisone; Humans; Hypotension, Orthostatic; Levodopa; Midodrine; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Thalamus; Tremor | 1983 |
Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1983 |
The effects of amantadine, rimantadine and levodopa on the frequency of fibrillation potentials in denervated muscle.
Topics: Acetylcholine; Adamantane; Amantadine; Animals; Electromyography; Levodopa; Muscle Contraction; Muscle Denervation; Rats; Receptors, Cholinergic; Rimantadine | 1984 |
Spasmodic torticollis and other idiopathic torsion dystonias. Medical management.
Topics: Adrenergic Agents; Amantadine; Antipsychotic Agents; Apomorphine; Benzodiazepines; Carbamazepine; Dystonia; Humans; Levodopa; Parasympatholytics; Torsion Abnormality; Torticollis | 1984 |
Effect of dopaminergic and GABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice.
Topics: Amantadine; Aminooxyacetic Acid; Amphetamine; Animals; Apomorphine; Baclofen; Dopamine; Electroshock; Female; Fluphenazine; gamma-Aminobutyric Acid; Haloperidol; Hydroxybutyrates; Levodopa; Male; Mice; Phenobarbital; Phenytoin; Receptors, Neurotransmitter; Seizures | 1980 |
[Influencing of the rate of taking root of the tumor by L-dopa, amantadine and measles vaccine in combination with gamma radiation (author's transl)].
Topics: Amantadine; Animals; Cyclic AMP; Cyclic GMP; Gamma Rays; Leukocyte Count; Levodopa; Measles Vaccine; Rats; Sarcoma, Experimental | 1980 |
Therapy of neurologic disorders in the elderly.
Topics: Aged; Amantadine; Anticoagulants; Brain Ischemia; Bromocriptine; Carbidopa; Dexamethasone; Drug Interactions; Heparin; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Trihexyphenidyl | 1984 |
The pharmacology of olivopontocerebellar atrophy.
Topics: Adult; Amantadine; Atrophy; Baclofen; Brain Diseases; Carbidopa; Cerebellar Ataxia; Female; Humans; Levodopa; Male; Middle Aged; Olivary Nucleus; Pons; Propranolol; Syndrome | 1984 |
The drug treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parasympatholytics; Parkinson Disease | 1984 |
[The influence of L-dopa and of thymus fraction on the survival rate of whole-body-irradiated mice].
Topics: Amantadine; Animals; Levodopa; Male; Measles Vaccine; Mice; Thymic Factor, Circulating; Thymus Hormones; Whole-Body Irradiation | 1982 |
[Treatment of Parkinson disease].
Topics: Amantadine; Dihydroxyphenylalanine; Drug Therapy, Combination; Ergot Alkaloids; Humans; Levodopa; Parkinson Disease | 1982 |
[Parkinsonism].
Topics: Aged; Amantadine; Humans; Levodopa; Middle Aged; Parkinson Disease | 1980 |
Computerized EEG study on drug-induced extrapyramidalism in schizophrenic patients.
Topics: Adolescent; Amantadine; Brain; Computers; Electroencephalography; Female; Glycolates; Haloperidol; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Pyramidal Tracts; Reference Values; Schizophrenia; Thiophenes; Trihexyphenidyl | 1982 |
Personal experience with a combination of drugs in subjects with dopa resistant Parkinson's disease.
Topics: Amantadine; Amitriptyline; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Humans; Hyperkinesis; Levodopa; Lithium; Middle Aged; Parkinson Disease; Trazodone | 1980 |
[New aspects of chronic occupational manganese poisoning].
Topics: Amantadine; Diagnosis, Differential; Humans; Levodopa; Manganese Poisoning; Occupational Diseases; Parkinson Disease, Secondary | 1982 |
[Treatment of Parkinson's syndrome].
Topics: Amantadine; Extrapyramidal Tracts; Humans; Levodopa; Parkinson Disease; Sulfates | 1982 |
Initial treatment of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Prognosis | 1982 |
The role of various forms of treatment in the management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergot Alkaloids; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1982 |
Parkinson's disease: new treatments.
Topics: Acetylcholine; Amantadine; Apomorphine; Bromocriptine; Carbidopa; Counseling; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Manifestations; Parkinson Disease; Physical Therapy Modalities; Receptors, Dopamine; Thalamus | 1981 |
[Crises in the course of Parkinson's disease].
Topics: Aged; Amantadine; Bromocriptine; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Psychotic Disorders | 1980 |
[A study on mental symptoms developing during the treatment of Parkinson's disease (author's transl)].
Topics: Aged; Amantadine; Delusions; Drug Therapy, Combination; Female; Hallucinations; Humans; Hypertension; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
[Amantadine in the therapy of Parkinson syndromes].
Topics: Amantadine; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Stimulation, Chemical | 1980 |
[Current treatment of Parkinsonian syndrome].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease, Secondary | 1980 |
[Initiation of treatment in Parkinson disease].
Topics: Adult; Age Factors; Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline | 1995 |
Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Blood Platelets; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Selegiline; Serotonin; Treatment Outcome | 1995 |
Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
Topics: Amantadine; Animals; Bromocriptine; Dopamine; Drug Synergism; Levodopa; Male; Memantine; Motor Activity; N-Methylaspartate; Parkinson Disease; Rats; Rats, Wistar; Selegiline | 1994 |
Hereditary parkinsonism with multiple system degeneration: beneficial effect of anticholinergics, but not of levodopa.
Topics: Adult; Amantadine; Basal Ganglia; Carbidopa; Cerebellar Ataxia; Cholinergic Antagonists; Consanguinity; Drug Resistance; Female; Genes, Recessive; Globus Pallidus; Homovanillic Acid; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Pedigree; Trihexyphenidyl | 1994 |
Day-night variation of urine volume in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Bromocriptine; Circadian Rhythm; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors; Trihexyphenidyl; Urine | 1994 |
Hyponatraemia due to amantadine hydrochloride and L-dopa/carbidopa.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Humans; Hyponatremia; Levodopa; Male | 1993 |
[A case of multiple system atrophy presenting a regular involuntary movement of the neck muscles synchronous with respiration].
Topics: Amantadine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Muscular Atrophy; Neck Muscles; Respiration; Trihexyphenidyl | 1993 |
Amantadine withdrawal and neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1993 |
Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts.
Topics: Adult; Amantadine; Antiparkinson Agents; Autopsy; Basal Ganglia; Brain Tissue Transplantation; Carbidopa; Cell Division; Cerebral Ventricles; Corpus Striatum; Embryo, Mammalian; Fetal Tissue Transplantation; Fetus; Gestational Age; Graft Survival; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Transplantation, Homologous | 1996 |
Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Treatment Outcome | 1996 |
Amantadine-induced "vocal" myoclonus.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Dysarthria; Female; Humans; Levodopa; Myoclonus; Neurologic Examination; Parkinson Disease; Verbal Behavior | 1996 |
Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter.
Topics: Amantadine; Animals; Benztropine; Carrier Proteins; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Piperazines; Rats; Reserpine | 1996 |
[Perioperative management of the patient with atypical Parkinson disease].
Topics: Amantadine; Anesthesia, General; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Intraoperative Complications; Levodopa; Male; Middle Aged; Neural Pathways; Neurologic Examination; Parkinson Disease; Postoperative Complications; Premedication; Preoperative Care; Substantia Nigra | 1996 |
Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Corpus Striatum; Dextroamphetamine; Dopamine; Ion Channels; Levodopa; Male; Motor Activity; Nicotinic Agonists; Olfactory Pathways; Parkinson Disease; Pyridines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Reserpine | 1997 |
Current therapy of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Humans; Levodopa; Parkinson Disease; Patient Selection; Selegiline | 1997 |
Triphasic waves in serotonin syndrome.
Topics: 1-Naphthylamine; Aged; Amantadine; Antiparkinson Agents; Brain Diseases; Carbidopa; Drug Combinations; Drug Therapy, Combination; Electroencephalography; Hallucinations; Humans; Levodopa; Male; Myoclonus; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Sertraline; Syndrome | 1997 |
The combined use of amantadine and l-dopa/carbidopa in the treatment of chronic brain injury.
Topics: Amantadine; Behavior; Brain Injuries; Carbidopa; Chronic Disease; Cognition; Drug Therapy, Combination; Female; Humans; Levodopa; Mental Status Schedule; Middle Aged; Neuropsychological Tests | 1997 |
Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa.
Topics: Aged; Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Pergolide | 1997 |
[Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Time Factors | 1997 |
Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Inappropriate ADH Syndrome; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Trihexyphenidyl | 1998 |
A frequency and correlation analysis of motor deficits in Parkinson patients.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Incidence; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Prognosis; Psychomotor Disorders; Psychomotor Performance; Selegiline; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 1998 |
[Dementia--Parkinson disease: role of antiglutamatergic drugs. Symposium: 4 April, Hamburg].
Topics: Amantadine; Antipsychotic Agents; Dementia; Humans; Levodopa; Movement Disorders; Parkinson Disease; Selective Serotonin Reuptake Inhibitors | 1998 |
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Injections, Subcutaneous; Levodopa; Macaca fascicularis; Neurologic Examination; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate | 1998 |
New use for an old drug: amantadine benefits levodopa-induced dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Neurologic Examination | 1998 |
Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group.
Topics: Aged; Algorithms; Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Diagnosis, Differential; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Care Planning | 1998 |
Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Amantadine; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Dextromethorphan; Dextrorphan; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; Movement Disorders; Parkinson Disease; Psychomotor Performance; Receptors, N-Methyl-D-Aspartate | 1998 |
Amantadine attenuates response alterations resulting from repetitive L-DOPA treatment in rats.
Topics: Amantadine; Analysis of Variance; Animals; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Rotation | 1998 |
Drug treatments of levodopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Patient Selection; Receptors, N-Methyl-D-Aspartate; Riluzole; Treatment Outcome | 1999 |
[Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Statistics, Nonparametric | 2000 |
Freezing of gait in patients with advanced Parkinson's disease.
Topics: Adult; Age of Onset; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Female; Freezing; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Regression Analysis; Retrospective Studies; Selegiline | 2001 |
Oculogyric-like crises in a 92-year-old woman with vascular Parkinsonism.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Brain; Brain Ischemia; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Levodopa; Magnetic Resonance Imaging; Ocular Motility Disorders; Parkinson Disease, Secondary; Treatment Outcome | 2001 |
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Recovery of Function | 2001 |
[L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
Topics: Amantadine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2001 |
A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system.
Topics: Aged; Amantadine; Binding, Competitive; Carbon Radioisotopes; Dopamine; Dopamine Agents; Dopamine Antagonists; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Presynaptic Terminals; Putamen; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Tomography, Emission-Computed | 2001 |
[The prevention of pneumonia in the elderly by dopamine agonists].
Topics: Aged; Amantadine; Angiotensin-Converting Enzyme Inhibitors; Dopamine Agonists; Humans; Levodopa; Pneumonia, Aspiration; Stroke | 2001 |
Medical management of Parkinson's disease.
Topics: Amantadine; Cholinergic Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Agonists; Humans; Levodopa; Neurologic Examination; Neuroprotective Agents; Parkinson Disease | 2002 |
Parkinson syndrome as a manifestation of mitochondriopathy.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Biopsy; DNA, Mitochondrial; Dopamine; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Mitochondrial Diseases; Muscle, Skeletal; Oxidative Phosphorylation; Parkinsonian Disorders; Point Mutation; Severity of Illness Index | 2002 |
[The use of amantadine sulfate in combined therapy of Parkinson's disease].
Topics: Aged; Amantadine; Carbidopa; Dopamine Agents; Drug Combinations; Drug Therapy, Combination; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Amantadine; Analysis of Variance; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Corpus Striatum; Dialysis; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Extracellular Space; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2003 |
The use of dopamine enhancing medications with children in low response states following brain injury.
Topics: Adolescent; Adult; Amantadine; Arousal; Awareness; Benzothiazoles; Brain Injuries; Bromocriptine; Child; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Methylphenidate; Neuropsychological Tests; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome; Unconsciousness | 2003 |
[Therapy for patients with early-stage Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Selegiline; Trihexyphenidyl | 2003 |
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Topics: Amantadine; Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesias; Female; Levetiracetam; Levodopa; Male; MPTP Poisoning; Piracetam | 2004 |
[Treatment in Parkinson disease].
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2004 |
Quality of life in Polish patients with long-lasting Parkinson's disease.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Depressive Disorder, Major; Dopamine Agents; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Poland; Quality of Life; Regression Analysis; Socioeconomic Factors; Surveys and Questionnaires; Time Factors | 2004 |
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Topics: Amantadine; Antiparkinson Agents; Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; GTP Cyclohydrolase; Heterozygote; Humans; Levodopa; Male; Parkinson Disease; Pedigree; Phenotype; Point Mutation | 2004 |
A young onset Parkinson's patient: a case study.
Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Dibenzothiazepines; Disease Progression; Dyskinesias; Humans; Levodopa; Male; Motor Skills; Nurse's Role; Parkinson Disease; Patient Advocacy; Patient Education as Topic; Quality of Life; Quetiapine Fumarate; Rhabdomyolysis; Severity of Illness Index; Social Support; Treatment Outcome | 2004 |
Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy; Deep Brain Stimulation; Drug Costs; Electrodes, Implanted; Enzyme Inhibitors; Humans; Levodopa; Models, Economic; Neurosurgical Procedures; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus | 2004 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Haloperidol; Idazoxan; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpine | 2005 |
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome | 2005 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
Treatment of progressive supranuclear palsy and corticobasal degeneration.
Topics: Amantadine; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Donepezil; Dopamine Agents; Dopamine Agonists; Dystonia; Globus Pallidus; Humans; Indans; Levodopa; Nerve Degeneration; Piperidines; Substantia Nigra; Supranuclear Palsy, Progressive | 2005 |
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Haplorhini; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Rotarod Performance Test; Time Factors | 2005 |
Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Hallucinations; Humans; Japan; Levodopa; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Time Factors | 2005 |
[Modern aproaches to the treatment of early stages of Parkinson disease].
Topics: Adult; Aged; Amantadine; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Piribedil; Severity of Illness Index | 2005 |
Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Dominance, Cerebral; Dyskinesias; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Postoperative Complications; Subthalamic Nucleus; Treatment Outcome | 2006 |
Initial pharmacotherapy in a population of veterans with Parkinson disease.
Topics: Age Factors; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Databases, Factual; Dementia; Dopamine Agonists; Drug Prescriptions; Drug Utilization; Geriatrics; Humans; Levodopa; Male; Medicine; Middle Aged; Neurology; Northwestern United States; Parkinson Disease; Practice Patterns, Physicians'; Primary Health Care; Psychiatry; Psychology; Retrospective Studies; Selegiline; Specialization; United States; United States Department of Veterans Affairs; Veterans | 2006 |
Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Deep Brain Stimulation; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Humans; Hypokinesia; Infusions, Intravenous; Injections, Subcutaneous; Levodopa; Middle Aged; Neurologic Examination; Optic Atrophy; Parkinson Disease | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Grooming; Hallucinations; Levodopa; Parkinsonian Disorders; Psychomotor Agitation; Psychotic Disorders; Statistics, Nonparametric; Stereotyped Behavior | 2006 |
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Cholinergic Antagonists; Dopamine Agonists; Drug Combinations; Female; Humans; Hungary; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Selegiline; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2008 |
Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Blood Platelets; Disease Progression; Female; Humans; India; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Young Adult | 2009 |
Medical treatment of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cognition Disorders; Corpus Striatum; Digestive System Physiological Phenomena; Dopamine Agonists; Enzyme Inhibitors; Humans; Hypotension, Orthostatic; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Motor Activity; Movement Disorders; Neurons; Parkinson Disease; Sleep Wake Disorders; Substantia Nigra | 2009 |
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Behavior, Animal; Disease Models, Animal; Dyskinesias; Extracellular Space; Levodopa; Male; Microdialysis; Morphinans; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation; Spiro Compounds; Time Factors | 2009 |
Room tilt illusion in Parkinson's disease: loss of spatial reference frames?
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agents; Humans; Illusions; Levodopa; Male; Orientation; Parietal Lobe; Parkinson Disease; Perceptual Disorders; Psychomotor Performance; Space Perception; Tomography, Emission-Computed, Single-Photon; Visual Cortex; Visual Pathways; Visual Perception | 2009 |
[The use of antiparkinsonism drugs in 92 cases in Xi'an city].
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; China; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Preference; Severity of Illness Index; Surveys and Questionnaires; Trihexyphenidyl | 2009 |
Progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) with fatal outcome, after the manifestation of an ampullary adenocarcinoma.
Topics: Adenocarcinoma; Aged; Amantadine; Ampulla of Vater; Antiparkinson Agents; Common Bile Duct Neoplasms; Fatal Outcome; Female; Humans; Indoles; Levodopa; Supranuclear Palsy, Progressive | 2010 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Schizophrenia, Paranoid; Syndrome | 2010 |
Management of punding in Parkinson's disease: an open-label prospective study.
Topics: Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quetiapine Fumarate; Stereotypic Movement Disorder | 2011 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics | 2011 |
Is pathological gambling in Parkinson's disease reduced by amantadine?
Topics: Aged; Amantadine; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Female; Gambling; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamates; Hydroxydopamines; Levodopa; Male; Mice; Microdialysis; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra | 2011 |
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Drug Synergism; Dyskinesia, Drug-Induced; Fructose; Levodopa; Male; MPTP Poisoning; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Sprague-Dawley; Topiramate | 2011 |
Westphal variant Huntington disease and refractory catatonia: a case report.
Topics: Adult; Amantadine; Carbidopa; Catatonia; Combined Modality Therapy; Dopamine Agents; Drug Combinations; Drug Resistance; Electroconvulsive Therapy; Female; Humans; Huntington Disease; Levodopa | 2011 |
Nasogastric medication for perioperative Parkinson's rigidity during anaesthesia emergence.
Topics: Amantadine; Anesthesia; Anesthesia Recovery Period; Anesthesia, General; Antiparkinson Agents; Carbidopa; Drug Combinations; Fracture Fixation, Internal; Fractures, Bone; Humans; Humerus; Intraoperative Awareness; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Perioperative Care | 2011 |
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Subthalamus | 2012 |
Profile of multiple system atrophy in Moroccan patients attending a movement disorders outpatient clinic in Rabat university hospital.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amantadine; Disease Progression; Dopamine Agonists; Female; Hospitals, University; Humans; Hypotension, Orthostatic; Levodopa; Magnetic Resonance Imaging; Male; Mental Disorders; Middle Aged; Morocco; Movement Disorders; Multiple System Atrophy; Outpatient Clinics, Hospital; Phenotype; Retrospective Studies; Sleep Disorders, Intrinsic; Symptom Assessment; Urination Disorders | 2013 |
Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
Topics: Aged; Amantadine; Antidepressive Agents; Antiparkinson Agents; Data Collection; Depression; Disease Progression; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Predictive Value of Tests; Prevalence; Prognosis; Prospective Studies; Risk Factors; Self Report; Sex Distribution; Surveys and Questionnaires | 2012 |
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Topics: Amantadine; Animals; Antiparkinson Agents; Cycloserine; Dextromethorphan; Dopamine Agents; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists | 2012 |
[Mexidant increases the effectiveness of levadopa treatment of Parkinson's disease].
Topics: Aged; Amantadine; Antioxidants; Antiparkinson Agents; Dopamine Agonists; Drug Administration Schedule; Drug Synergism; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Levodopa; Lipid Peroxidation; Lipoproteins; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Pyridines | 2012 |
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2013 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Disease Models, Animal; Dopamine Agents; Dyskinesias; Immunohistochemistry; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Neurons; Oxidative Stress; Parkinson Disease; Positron-Emission Tomography; Thiazoles | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Bromocriptine; Calcium; Catalepsy; Dopamine Agonists; Food, Formulated; Levodopa; Magnesium; Magnesium Deficiency; Male; Mice; Parkinson Disease, Secondary; Receptors, Dopamine; Risk Factors; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline | 2013 |
TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.
Topics: Amantadine; Animals; Azabicyclo Compounds; Cyclopropanes; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Nicotinic Agonists | 2013 |
[Livedo reticularis secondary to amantadine in a patient with Parkinson disease].
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Livedo Reticularis; Parkinson Disease | 2014 |
Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report.
Topics: Adolescent; Amantadine; Carbidopa; Cerebral Palsy; Cognition Disorders; Dopamine Agonists; Dopamine Antagonists; Drug Combinations; Haloperidol; Humans; Levodopa; Male; Psychomotor Disorders | 2013 |
Amantadine's role in the treatment of levodopa-induced dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2014 |
Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Patient Selection; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2014 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2014 |
Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.
Topics: Amantadine; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Delusions; Dopamine Agents; Hallucinations; Humans; Illusions; Levodopa; Logistic Models; Multivariate Analysis; Parkinson Disease; Psychotic Disorders; Risk Factors; Selegiline; Surveys and Questionnaires | 2014 |
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Topics: Amantadine; Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Imidazoles; Levodopa; Macaca fascicularis; MPTP Poisoning | 2014 |
Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?
Topics: Amantadine; Antiparasitic Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals | 2014 |
A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Brain; Chorea; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Spinocerebellar Ataxias; TATA-Box Binding Protein; Trinucleotide Repeats | 2016 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; Medial Forebrain Bundle; Microinjections; Nitroprusside; Oxidopamine; Parkinson Disease; Rats | 2016 |
Extended-Release Amantadine-A Smart Pill for Treatment of Levodopa-Induced Dyskinesia but Does the Evidence Justify the Cost?
Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2017 |
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Topics: Aged; Amantadine; Double-Blind Method; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Treatment Outcome | 2017 |
Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Topics: Amantadine; Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Metformin; Mice, Inbred C57BL; Parkinson Disease; Signal Transduction | 2018 |
ADS 5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia-Reply.
Topics: Amantadine; Antiparkinson Agents; Dyskinesias; Humans; Levodopa | 2017 |
ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Dyskinesias; Humans; Levodopa | 2017 |
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Drug Compounding; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2017 |
Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Quality of Life | 2019 |
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Camphanes; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Pyrazoles; Receptor, Cannabinoid, CB2 | 2020 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Drug Repositioning; Indans; Isradipine; Larva; Levodopa; Locomotion; Motor Activity; Oxidopamine; Parkinson Disease; Phenotype; Zebrafish | 2020 |
A Real-Life Search for the Optimal Set of Conversion Factors to Levodopa-Equivalent-Dose in Parkinson's Disease Patients on Polytherapy.
Topics: Aged; Amantadine; Antiparkinson Agents; Catechols; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies | 2020 |
Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
Topics: Amantadine; Animals; Antiparkinson Agents; Bridged Bicyclo Compounds; Corpus Striatum; Dyskinesia, Drug-Induced; Electrophysiology; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2020 |
Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease.
Topics: Amantadine; Apomorphine; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gonorrhea; Humans; Levodopa; Middle Aged; Parkinson Disease; Sexual Dysfunctions, Psychological; Tetrahydronaphthalenes; Thiophenes | 2020 |
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats, Sprague-Dawley | 2020 |
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
Topics: Amantadine; Animals; Antiparkinson Agents; CHO Cells; Corpus Striatum; Cricetulus; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Receptors, N-Methyl-D-Aspartate; Synaptic Potentials | 2020 |
The selective 5-HT
Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Serotonin 5-HT1 Receptor Agonists | 2020 |
[Amantadine in the treatment of Parkinson's disease. New opportunities in the context of COVID-19].
Topics: Amantadine; Antiparkinson Agents; COVID-19; Humans; Levodopa; Parkinson Disease; SARS-CoV-2 | 2021 |
Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2022 |
Striatal Neuronal Ensembles Reveal Differential Actions of Amantadine and Clozapine to Ameliorate Mice L-DOPA-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Calcium; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Neurons; Oxidopamine | 2022 |
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Vilazodone Hydrochloride | 2022 |
[Parkinson's Disease with Intolerable Painful Dyskinesia: Standard Treatment and Subsequent Tips].
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Pain; Parkinson Disease | 2022 |
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidinones; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tryptamines | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine; Levodopa; Macaca fascicularis; Neuroprotective Agents; Parkinsonian Disorders; Pilot Projects; Prodrugs; Receptors, N-Methyl-D-Aspartate | 2022 |
Time until modification of antiparkinsonian therapy in a group of patients from Colombia.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Colombia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2023 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
Amantadine toxicity causing visual hallucinations.
Topics: Amantadine; Antiparkinson Agents; Female; Hallucinations; Humans; Levodopa; Multiple Sclerosis | 2023 |
Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.
Topics: Amantadine; Animals; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Knockout; Parkinson Disease | 2023 |